Introduction {#Sec1}
============

Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer among females, accounting for 23% of total cancer diagnoses and 14% of overall cancer deaths (Jemal A et al. [@CR32]). Moreover, BC is now the leading cause of cancer-related death among females in developing countries, a shift from the previous decade when cervical cancer was the most common cause of cancer-related death. Although cancer incidences and patterns differ according to level of human development, female BC is the only type of cancer that is common in all regions of the world. Thus, the global control of BC through both early detection and primary prevention is a high priority (Bray et al. [@CR5]). Specifically in the context of this study, there is a high incidence of BC in the female population in Brazil with more than 50 new cases diagnosed per 100,000 women every year (INCA [@CR25]).

Major advances in the early diagnosis of some cancers and a better understanding of the pathogenesis of the disease have led to risk reduction and prevention strategies. These advances as well as improvements in therapy have all contributed to declines in cancer-related death rates (Jemal et al. [@CR31]). However, these successes have come with substantial increases in cost, causing a serious financial burden on patients, families, and society at large (Meropol et al. [@CR45]). Currently, the most effective method for preventing premature mortality and morbidity due to BC is the increased use of screening programs and adjuvant therapies (Berry et al. [@CR3]). In particular, effective early detection strategies are preferred to adjuvant therapies because they result in less morbidity.

For the past 30 years, conventional screen-film mammography (SFM) has been the method of choice for the radiological evaluation of the breast (Tabar & Dean [@CR66]). The demonstration of the efficacy of mammography in reducing BC mortality by approximately 15% in younger women (\<50 years) (Nelson et al. [@CR53]) led to recommendations in some countries to introduce routine screening programs for this subgroup (Schopper & de Wolf [@CR59]). However, considerable controversy over whether screening is effective for women aged 40--49 years has halted the adoption of a broad screening approach. Further, because SFM has lower sensitivity mainly due to the greater breast density and higher rates of tumor growth in younger women (Buist et al. [@CR6]), full-field digital mammography (FFDM) has been shown to be superior to SFM in this subgroup (Souza et al. [@CR64]; Pisano et al. [@CR57]; Skaane et al. [@CR60]).

FFDM is based on a different technology, in which each exposure produces a digital image (Tice & Feldman [@CR67]). Although BC age-targeted screening (digital for women \<50 years) is reasonably cost-effective in the US (Tosteson et al. [@CR68]), no studies of the cost-effectiveness of FFDM screening in younger women have yet been carried out in middle-income countries. The objective of this study is thus to explore the cost-effectiveness of population-based BC screening using different strategies for women aged 40--49 years in the Brazilian public health system.

Material and methods {#Sec2}
====================

Mathematical model {#Sec3}
------------------

The developed mathematical model was constructed using decision analysis software (TreeAgePro2009 Suite, release 1.0.2, Tree Age Software, Inc., Williamstown, MA). Specifically, a Markov model was used to compare populations of young women in Brazil. The structure of the model (Figure [1](#Fig1){ref-type="fig"}) is similar to other models used for BC screening programs and characterizes the complexity of the natural history of the disease (e.g., invasive stages are defined following the tumor--node--metastasis classification (Edge et al. [@CR14]; van Oortmarssen et al. [@CR70]; Szeto & Devlin [@CR65]; Rojnik et al. [@CR58]).Figure 1**The disease process model for breast cancer.**

In the real world, women diagnosed with BC have a relatively high risk of developing a new cancer or a recurrent disease. Women who develop a recurrent disease will create extra cost and utilities for the state in line with the basal risk of recurrence of the higher Markov state.

The micro simulation approach with a cycle length of 1 year with half-cycle correction was chosen for this study. BC incidence, mammography sensitivity, mortality, and relative survival rate were modeled as time-dependent transition probabilities.

We considered the following seven BC screening strategies for women aged 40--49 years: (A) usual care; (B) annual SFM; (C) SFM every 2 years; (D) annual FFDM; (E) FFDM every 2 years; (F) "age-targeted digital" (i.e., annual FFDM for the 40--49 age group and annual SFM for the 50--69 age group); and (G) "age-targeted digital" (annual FFDM for the 40--49 age group and SFM every 2 years for the 50--69 age group). These strategies were based on the findings of previous studies (Schopper & de Wolf [@CR59]; US Preventive Services Task Force [@CR69]) and they included the current status of the Brazilian public health system (Strategy A "no formal BC screening" as the base case). According to DATASUS, the Brazilian public health system database, the annual utilization of SFM is approximately 17.5% in women above 50 years (Ministério_Saúde_Brasil, DATASUS [@CR47]).

To determine whether the increased costs of screening strategies are warranted by health gains compared with usual care, we assessed the cost-effectiveness of these seven screening strategies from a public healthcare perspective. The time horizon covered the full lifetimes of the sample population from age 40 onward. Mammography screening stops after 69 years as recommended by the Brazilian National Cancer Institute (INCA) (INCA [@CR24]). The starting age for the micro simulation ranged from 40 to 49 years based on the Brazilian population census (IBGE [@CR23]).

Model calibration {#Sec4}
-----------------

Data on age-dependent cancer incidence were obtained from the Population-based Cancer Registry in Brazil (INCA [@CR28]). The clinical-stage distributions for usual care and screening strategies were used from INCA (INCA [@CR29]) and from the literature, respectively. Table [1](#Tab1){ref-type="table"} presents the main parameters used in the model.Table 1**Main parameters used in the base case and sensitivity analyses**VariablesScreening test performanceDistribution/commentsReferenceMeanMinimumMaximumMammography coverage18%10%30%Uniform(Ministério_Saúde_Brasil, DATASUS [@CR47])Mammography coverage ^ǁ^70%55%85%Uniform(Lilliu et al. [@CR37])Sensitivity of SFM (40--49 years)76%60%85%Effectiveness data from large population(Kerlikowske et al. [@CR35])Sensitivity of FFDM (40--49 years)82%65%90%Effectiveness data from large population(Kerlikowske et al. [@CR35])Sensitivity of SFM (50--59 years)85%65%90%Effectiveness data from large population(Kerlikowske et al. [@CR35])Sensitivity of FFDM (50--59 years)80%65%90%Effectiveness data from large population(Kerlikowske et al. [@CR35])Sensitivity of SFM (60--69 years)83%65%90%Effectiveness data from large population(Kerlikowske et al. [@CR35])Sensitivity of FFDM (60--69 years)90%65%95%Effectiveness data from large population(Kerlikowske et al. [@CR35])Treatment complication (yearly) - Chemotherapy16%10%20%Resource utilization database(Hassett et al. [@CR18])Treatment complication (yearly) -- Endocrine therapy5%1%10%Resource utilization database(Hassett et al. [@CR18])Overdiagnosis5%030%Systematic review estimate(Smith & Duffy [@CR62])**Cancer stage distributionMeanCI**^**\***^**95%**DCIS (clinical diagnostic)6.1%4.9--7.3%Beta (α = 97; β = 1494)(INCA [@CR27]; Martins et al. [@CR42])State 1 (clinical diagnostic)14%13.1--16.6%Beta (α = 232; β = 1329)(INCA [@CR27]; Martins et al. [@CR42])State 2 (clinical diagnostic)38.6%36.5--40.5%Beta (α = 915; β = 1455)(INCA [@CR27]; Martins et al. [@CR42])State 3 (clinical diagnostic)34.7%32.4--37.1%Beta (α = 546; β = 1028)(INCA [@CR27]; Martins et al. [@CR42])State 4 (clinical diagnostic)10.8%NAComplementary(INCA [@CR27]; Martins et al. [@CR42])CDIS (screening diagnostic)6.1%NADynamic range ^∫^(Kerlikowske et al. [@CR35])State 1 (screening diagnostic)58%^Ξ^NAEffectiveness data from large population(Kerlikowske et al. [@CR35])State 2 (screening diagnostic)32.4%^Ξ^NAEffectiveness data from large population(Kerlikowske et al. [@CR35])State 3 (screening diagnostic)8.3%^Ξ^NAEffectiveness data from large population(Kerlikowske et al. [@CR35])State 4 (screening diagnostic)1.3%^Ξ^NAEffectiveness data from large population(Kerlikowske et al. [@CR35])**Transition probabilitiesBC RecurrenceMeanRangeLocalRegional/systemic**CDIS0.008/y0.002--0.014/y50--98%2--50%(Baxter et al. [@CR2]; Meijnen et al. [@CR44])Stage 10.030/yNA16--47%53--84%(Hirsch et al. [@CR20]; Hirsch et al. [@CR21])Stage 20.087/yNA19--56%44--81%(Wapnir et al. [@CR73])Stage 30.283/y0,11--0,28/y19--56%19--56%(Wapnir et al. [@CR73])**BC DeathMeanRange**CDIS0.002/y0.002--0.003/y(Ernster et al. [@CR15])Stage 10.009/yNA(de Oliveira et al. [@CR12])Stage 20.031/yNA(de Oliveira et al. [@CR12])Stage 30.090/yNA(de Oliveira et al. [@CR12])Stage 40.270/y0.20--0.34(de Oliveira et al. [@CR12])**Relative riskDistribution/commentsMean**Adjuvant Taxane chemotherapy^§^0.86Log-Normal (μ = −0.15;σ=0.07)(Peto et al. [@CR56])Adjuvant Aromatase inhibitor^§¶^0.82Log-Normal (μ = −0.20;σ=0.12)(Dowsett et al. [@CR13])Adjuvant Trastuzumab therapy ^§‡^0.61Log-Normal (μ = −0.49;σ=0.06)(Perez et al. [@CR55])Screening vs. non-screening cancer cases^Φ^0,62Log-Normal (μ= − 0.48;σ=0.12)(Mook et al. [@CR48])Advanced disease - Luminal A vs. Luminal B^¥^1.42Log-Normal (μ = 0.34;σ=0.12)(Kennecke et al. [@CR33])Advanced disease - Luminal A vs. HER2 + ^¥^1.90Log-Normal (μ=0.64;σ=0.11)(Kennecke et al. [@CR33])Advanced disease - Luminal A vs. Triple negative^¥^1.62Log-Normal (μ = 0.48;σ=0.11)(Kennecke et al. [@CR33])**Relative odds ratioDistribution/commentsMean**Diagnostic cancer downstage (FFDM under 50 years)0.54Log-Normal (μ= − 0.654;σ=0.307)(Souza et al. [@CR64])**MeanMinimumMaximum**Discount rate5%0%10%Brazilian Health Economic Guidelines(Ministério_Saúde_Brasil [@CR46])**Costs (Brazilian Real)MeanMinimumMaximum**Medical visit10525DATASUS(Ministério_Saúde_Brasil, DATASUS [@CR47])FFDM684590Estimated^∀^(Souza [@CR63])SFM453060DATASUS(Ministério_Saúde_Brasil, DATASUS [@CR47])Biopsy429150700Gamma (α = 14.93; λ = 0.03)(Souza [@CR63])Recall SFM15250250Aggregate costs(Souza [@CR63])Recall FFDM197100300Aggregate costs(Souza [@CR63])Staging early BC^Ψ^509250750Gamma (α = 3.09 λ=0.01)(Souza [@CR63])Staging locally and advanced cancer^Δ^592200800Gamma (α = 2.52 λ=0.04)(Souza [@CR63])Invasive cancer stage 1 (first year)6,5022,50011,500Aggregate costs(Souza [@CR63])Invasive cancer stage 2 (first year)15,6106,50024,500Aggregate costs(Souza [@CR63])Invasive cancer stage 3 (first year)18,6389,50027,500Aggregate costs(Souza [@CR63])Invasive cancer stage 4 (first year)12,4526,50020,500Aggregate costs(Souza [@CR63])Invasive cancer stage 1 (≥ 2 year)6022001,000Aggregate costs(Souza [@CR63])Invasive cancer stage 2 (≥ 2 year)6772001,200Aggregate costs(Souza [@CR63])Invasive cancer stage 3 (≥ 2 year)7422001,600Aggregate costs(Souza [@CR63])Invasive cancer stage 4 (≥ 2 year)12,439400020,000Aggregate costs(Souza [@CR63])**UtilitiesMeanCI**^**\***^**95%**Healthy woman0.800NASouth of Brazil population^⊥^(Cruz [@CR10])Healthy woman -- false positive mammography0.795NAEstimated^∴^(Cruz [@CR10])Non metastatic BC^χ^ -- follow-up0.7720.63--0.90Normal distribution(Souza [@CR63]; Cruz [@CR10])Early BC^χ^ -- Adjuvant Endocrine Therapy0.7620.62--0.91Normal distribution(Souza [@CR63]; Cruz [@CR10])Early BC^χ^ -- Adjuvant Chemotherapy0.7390.61--0.87Normal distribution(Cruz [@CR63]; Cruz [@CR10])Clinical Stage 3 -- Adjuvant Endocrine Therapy0.7600.59--0.95Normal distribution(Souza [@CR63]; Cruz [@CR10])Clinical Stage 3 -- Adjuvant Chemotherapy0.7000.63--0.78Normal distribution(Souza [@CR63]; Cruz [@CR10])Clinical Stage 4 -- Advanced disease0.6800.57--0.80Normal distribution(Souza [@CR63]; Cruz [@CR10])^ǁ^ Screening strategies; NA: not applicable; ^∫^ time and screening coverage-dependent (increase in the DCIS rate with the introduction of the screening program); ^Ξ^ relative to invasive cancer (excluding DCIS); ^§^ Relative risk of BC death in clinical stage 2 and 3 patients; ^¶^ hormone-positive patients; ^‡^ HER2-positive patients; ^Φ^ Relative risk of BC death; ^¥^ Relative risk of BC death in advanced disease (stage 4) according to prognostic subtype; ^∀^ Plausible estimate 50% above SFM reimbursement value; ^Ψ^ clinical stages 1 and 2; ^Δ^ clinical stages 3 and 4; ^\*^ confidence interval; ^⊥^ Porto Alegre city; ^∴^Considering the mean of non-metastatic BC utility (0.77) and a false positive as a 2-month period of disutility (0.80--0.77= \[(0.03)\*(0.16 year)=0.005\] →0.80--0.005=0.795; ^χ^*in situ*, stage 1, stage 2, and stage 3 patients.

Transitions to Markov states are governed by the rate of incidence, clinical-stage distribution data, and sojourn time. We modeled for an increase in the incidences of in situ carcinomas through the introduction of screening mammography (Kerlikowske [@CR34]). Ten years after the introduction of these screening programs, ductal carcinoma in situ (DCIS) incidence rates were assumed to have stabilized.

Moreover, evidence of better prognostic screening compared with the pre-screening era for in situ cancer cases was incorporated into our model (Ernster et al. [@CR15]), while over diagnosis was adjusted for confounding and lead time bias according to the findings of Smith and Duffy (Smith & Duffy [@CR62]). The risks and benefits of screening schedules were also adapted from Mandelblatt et al. (Mandelblatt et al. [@CR40]). BC prognosis subgroups were then determined for advanced disease status: Luminal A, Luminal B, HER2-enriched, and triple negative (Kennecke et al. [@CR33]). Screened BC has been shown to have independently lower mortality rates compared with non-screened BC (Mook et al. [@CR48]). Finally, we also adjusted BC recurrence risk based on BC subgroup, exposure to adjuvant/palliative chemotherapy, adjuvant/palliative trastuzumab, and adjuvant/palliative endocrine therapy based on previous findings (Perez et al. [@CR55]; Hortobagyi [@CR22]; Mauri et al. [@CR43]; Mouridsen et al. [@CR51]; Mouridsen et al. [@CR50]; Slamon et al. [@CR61]).

Patterns of stage-specific treatments were adapted from DATASUS and from the literature. For DCIS, two treatments were possible: surgery with or without radiotherapy (Wapnir et al. [@CR74]; Baxter et al. [@CR2]; Meijnen et al. [@CR44]). For invasive BC, five treatments were possible: surgery, anti-HER2 adjuvant biologic therapy, radiotherapy, chemotherapy, and endocrine therapy. The last three treatments could be used in an adjuvant as well as in a palliative setting, while anti-HER2 therapy was only allowed in adjuvant stage 2 and 3 settings for HER2-positive patients for 1 year (Perez et al. [@CR55]). Further, the sensitivity of the mammography in the base case was adapted from Breast Cancer Surveillance Consortium (BCSC) data (Kerlikowske et al. [@CR35]). The BCSC database was chosen because it is the largest source of effectiveness data from population screening using both film and digital technology.

The deployment of an FFDM screening program may cause higher recall rates compared with an SFM-based program (Bluekens et al. [@CR4]). For the first round of screening in the present study (prevalence screening), recall rates were 4.29% and 3.41% for FFDM and SFM, respectively. For the second round (incidence screening), recall rates were 1.69% and 1.01% (Bluekens et al. [@CR4]). We assumed that all recalled women would undergo another mammography and/or ultrasound. Approximately 5% and 3% of the recalled women underwent fine needle aspiration and surgical biopsy, respectively (Moss et al. [@CR49]).

All death rates were adapted from the Brazilian Institute of Geography and Statistics Census (2010) and BC deaths were calibrated based on the Mortality Information System of Brazil (DATASUS [@CR11]).

We tested whether the model was calibrated according to the life expectancy of Brazilian women (IBGE [@CR23]). The model does not include input parameters for life expectancy, which is estimated indirectly as a function of the parameters for relapse rates, progression, and overall and BC deaths. Thus, the life expectancy of Brazilian women was defined as an appropriate parameter to validate the model in Brazil. Figure [2](#Fig2){ref-type="fig"} presents the life expectancy predicted in the model at a 95% confidence interval.Figure 2**Model predicted life expectancy and 95% confidence interval for women 40 years and older, and estimates from the Brazilian Institute of Geography and Statistics Cencus.**

Screening and participation rates {#Sec5}
---------------------------------

There is no formal screening activity in Brazil (despite some isolated initiatives at a regional level). Therefore, opportunistic screening is considered to be usual care in the Brazilian public health system. DATASUS shows that approximately 18% of women above 50 have undergone SFM (Ministério_Saúde_Brasil, DATASUS [@CR47]). A Brazilian prospective cohort achieved a similar opportunistic screening rate of approximately 24% (Marchi & Gurgel [@CR41]). Finally, annual participation rates ranged from 18% to 70%.

Costs and health outcomes {#Sec6}
-------------------------

Table [1](#Tab1){ref-type="table"} presents the costs and utilities applied in the model. Total costs consist of the costs of primary care consultancy, mammography screening, additional work-up exams (when required), cancer diagnostic procedures (images, biopsy, pathology), cancer staging (images), cancer treatment (surgery, radiotherapy, chemotherapy, anti-HER2, and endocrine therapy), and cancer follow-up. Costs were obtained from Ministério_Saúde_Brasil, DATASUS ([@CR47]) and the BC database of resource utilization in the public healthcare system in Brazil (Souza [@CR63]). All costs are expressed in 2010 Brazilian Real (US\$ 1 = R\$ 1.67). Quality-adjusted life years (QALYs) were estimated based on the patient's SF-6D scores (Souza [@CR63]; Cruz [@CR10]).

Base case analysis {#Sec7}
------------------

Using a set of natural history input parameters, we calculated the expected costs and effectiveness of each strategy in base case and sensitivity analyses. The costs and effects of each simulated screening program were then assessed. Future costs and health effects (e.g., life years and utilities losses) were discounted at a rate of 5% according to the Brazilian Guidelines for Health Technology Assessment (Ministério_Saúde_Brasil [@CR46]). After ranking them in order of increasing costs and eliminating all dominant strategies (greater cost and fewer benefits than any other combination of strategies), we calculated incremental cost-effectiveness ratios (ICERs).

Since there is no recommended threshold to determine whether an intervention is cost-effective in Brazil (Ministério_Saúde_Brasil [@CR46]), we adapted the recommendations of the World Health Organization, which suggests that a cost-effective intervention would avert one additional disability-adjusted life year for less than three times average per capita GDP (World Health Organization [@CR75]). We assumed that society's willingness to pay (WTP) for one additional disability-adjusted life year was equivalent to its WTP for one QALY. This approach has been used in previous economic evaluations performed in Brazil and in other middle-income countries (Goldie et al. [@CR16]; Goldie et al. [@CR17]; Vanni et al. [@CR71]; Vanni et al. [@CR72]). Programs that were more costly and less effective than other programs were immediately ruled out as inefficient (i.e., according to the simple dominance principle). The remaining programs constituted the frontier of efficient screening programs.

Sensitivity analysis {#Sec8}
--------------------

To assess uncertainty in the model, one-way, scenario, and probabilistic sensitivity analyses were conducted. In one-way sensitivity analysis, the key parameters were varied using minimum and maximum values, as shown in Table [1](#Tab1){ref-type="table"}. A probabilistic sensitivity analysis was also performed to explore joint uncertainty across parameters. By sampling the distribution of the model parameters, we generated 10,000 estimates for the costs and effects of each strategy. These estimates were plotted on a cost-effectiveness plane and cost-effectiveness acceptability curves were used to depict the level of uncertainty for the optimal strategy at different WTP thresholds for an additional QALY (Barton et al. [@CR1]).

Results {#Sec9}
=======

Base case analysis {#Sec10}
------------------

In the base case analysis, with a simulated cohort starting at 40 years, we found that the mean survival period (adjusted for quality) for usual care was 14,498, at a lifetime cost of R\$ 2,075. All other screening strategies were associated with higher QALYs and additional costs. Table [2](#Tab2){ref-type="table"} presents the ICER results for the base case analysis. The discounted QALYs for the seven strategies were similar to those found in previous BC screening studies, while the differences between these strategies were small (Tosteson et al. [@CR68]; Rojnik et al. [@CR58]). However, there were greater differences in terms of expected lifetime costs.Table 2**Base-case incremental cost effectiveness results**StrategyDiscounted costs (Brazilian Real)Discounted effect (QALY)Order of non-dominated strategiesICER (R\$/QALY)**Strategy A - Usual care**2,07514,4981---**Strategy B - SFM annual**2,31814,546313,131**Strategy C -- SFM every 2 years**2,12514,53221,509**Strategy D -- FFDM annual**2,56414,548**Strategy E -- FFDM every 2 years**2,25914,533**Strategy F -- FFDM (\<50) and SFM (50--69) annual**2,39314,549430,520**Strategy F -- FFDM annual (\<50) and SFM (50--69) every 2 years**2,25414,538

Thus, the costs and effectiveness of the strategies were considered to identify which strategy represented better value for money. Figure [3](#Fig3){ref-type="fig"} and Table [2](#Tab2){ref-type="table"} show that usual care (Strategy A) was the cheapest but least effective strategy. Adopting SFM every 2 years (Strategy C) was slightly more costly but also more effective, yielding an ICER of R\$ 1,509 per QALY gained. The next best alternative also adopted SFM, but now annually (Strategy B), which was cost-effective at an additional R\$ 13,131 per QALY gained. FFDM annual screening (Strategy E) was dominated by Strategy F, which is an age-targeted option, with FFDM used annually until 49 years and SFM annually from 50 to 69 years. For younger women (\<50 years), this is the most effective strategy. With an ICER of R\$ 30,520, Strategy F could also be considered to be a cost-effective strategy for an emerging country such as Brazil.Figure 3**Cost Effectiveness plane (base-case).**

Sensitivity analysis {#Sec11}
--------------------

In the one-way sensitivity analysis, the ranking of the seven strategies remained unchanged for most model parameters. The results were most sensitive to changes in the coverage of opportunistic screening under usual care (Strategy A). At a coverage rate of approximately 30%, SFM every 2 years showed cost savings. Although the discount rate and BC incidence seemed to play an important role in determining the magnitude of ICERs, they did not change the order of the strategies that composed the cost-effectiveness frontier.

Figure [4](#Fig4){ref-type="fig"} presents the range of ICERs according to BC incidence, age distribution, and mammography coverage by Brazilian region (INCA [@CR28]; MS [@CR52]). In regions that have a lower BC incidence (e.g., Belem and Cuiaba city), ICERs have a higher probability of not being cost-effective (R\$ 257,889 and R\$ 49,362, respectively). On the contrary, for regions that have a higher BC incidence (e.g., São Paulo and Recife), the ICER is approximately R\$ 21,000. The best scenario was in Porto Alegre, with an ICER of R\$ 15,300.Figure 4**Sensitivity analysis.** Shown is the range of the incremental cost-effectiveness ratios (ICERs) as a result of varying parameters and assumptions for screening strategy (breast cancer incidence, populational age distribution and mammography coverage).

Figure [5](#Fig5){ref-type="fig"} reports the results of the probabilistic sensitivity analysis. By adopting the threshold suggested by the Commission for Macroeconomics in Health for cost-effectiveness interventions (R\$ 17,869/QALY), and by considering both SFM strategies (annual and every 2 years), we found a high probability that SFM is a cost-effective approach for the Brazilian public health system (approximately 70% of the simulations). Moreover, at a much lower ICER of R\$ 6,000/QALY, SFM every 2 years was cost-effective in more than 95% of the simulations.Figure 5**Cost Effectiveness acceptability curve (dominated strategies not shown).**

Nonetheless, it is important to recognize that FFDM is increasingly used by institutions in Brazil. When we consider a cost-effective threshold of three times national GDP (R\$ 53,607/QALY), we found a high probability that an age-targeted strategy (e.g., Strategy F) would be cost-effective (approximately 60% of the simulations). Considering a WTP of R\$ 20,000/QALY, 10% of the simulations with Strategy F would be considered to be cost-effective. In the case of a WTP of R\$ 100,000/QALY, this figure grew to 70% of the simulations.

Discussion {#Sec12}
==========

BC incidence varies considerably throughout the world; indeed, age-standardized incidence is approximately fourfold higher in high-income countries in North America and Western Europe compared with countries that have a lower per capita income (Legorreta et al. [@CR36]). A strong correlation between the age-standardized incidence of BC and average GDP per capita has been demonstrated (Lilliu et al. [@CR37]). However, in many low- and middle-income countries, incidence is increasing faster than that in developed nations, where incidence is already high (Cody [@CR9]).

In many Western countries, mammography screening has become the standard of care for the early detection of BC. Despite its widespread use, however, mammography is a far from a perfect means of early detection. Several limitations have been recognized, such as in the areas of false positive results, ethnic and biological differences, social and cultural barriers, and the harm-to-benefit ratio (Lu et al. [@CR39]). Some studies have demonstrated that SFM can be cost-effective in Western countries (\<US\$ 50,000/QALY) (Tosteson et al. [@CR68]; Szeto & Devlin [@CR65]; Lindfors & Rosenquist [@CR38]), whereas its benefit is more questionable in low- and middle-income countries (Rojnik et al. [@CR58]; Okonkwo et al. [@CR54]; Jakubowski et al. [@CR30]).

Our Markov model shows that using SFM to screen for BC is a cost-effective strategy for the public health system in Brazil, a middle-income country. Considering the cost-effective threshold given by Brazil's GDP per capita, SFM every 2 years is the strategy that has the best cost-effectiveness profile (ICER below the threshold and high probability of being cost-effective in the probabilistic sensitivity analysis). Gains in QALYs are likely to occur due to the earlier diagnostic stage of BC in women, which compensates for the additional cost of mammography screening, medical consultations, false positive results, the increase in the incidence of DCIS after the screening program has been deployed, and the over diagnosis of cancer cases. This BC treatment strategy allows for a better cure rate and lower expenses and health resource utilization (Legorreta et al. [@CR36]; Lilliu et al. [@CR37]; Lu et al. [@CR39]; Butler et al. [@CR7]; Hillner [@CR19]; Cady [@CR8]).

An important strength of our model is the use of the BC database, which reflects the standards of care in disease management. The base case reflects the life expectancy of Brazilian women, and QALYs were estimated from BC patients. QALYs for a healthy state were calculated based on the Brazilian population (Cruz [@CR10]).

According to a recent government estimate, Brazil has enough mammography devices to cover more than 70% of Brazilian women aged above 50 years (MS [@CR52]). Further, the country has deployed a program to improve the quality of mammograms in the Brazilian public health system (INCA [@CR26]). This adequate screening capacity along with a quality program and cost-effective data make the adoption of a national BC screening program feasible and desirable in Brazil. In this study, we demonstrate that a BC film-screening program every 2 years is a cost-effective strategy.

Regarding digital mammography screening strategies, annual screening by FFDM (Strategy E) was dominated by Strategy F (age-targeted screening). As presented in Figure [4](#Fig4){ref-type="fig"}, there was great variability in ICERs across the country, mainly related to local BC incidence. This finding suggests the importance of recognizing that for a large heterogeneous country as Brazil regionalized health policy must be considered by decision makers. For instance, in the north, digital mammography screening should not be recommended due to unfavorable cost-effectiveness. By contrast, in the southeast and south of the country, where BC incidences are higher, a digital age-targeted screening program could be considered to be a good investment in terms of value of money.

Moreover, if we consider that most mammography machines in public institutions are obsolete (\>8 years old), the acquisition of replacement equipment is crucial. Thus, health policies that incentivize the acquisition of digital technology devices must be discussed for those regions with high BC incidence (mainly the southeast, south, and some areas of the northeast). In our view, this implementation should be gradual in order to minimize the budget impact from a short-term perspective, but it would allow the public system to move towards more modern technology. Although the main advantage of FFDM is seen for younger women (\<50 years), other potential benefits of digitalization could be anticipated, such as the possibility of teleradiology and the more reliable retrieval of exams for future comparisons.

Our model estimates of incremental QALYs are similar to those reported in previous studies in high-income countries (Tosteson et al. [@CR68]; Szeto & Devlin [@CR65]; Lindfors & Rosenquist [@CR38]), and we draw similar conclusions about the advantages of BC screening in the younger population. To the best of our knowledge, however, this is the first cost-effectiveness analysis that focuses on age-targeted digital mammography screening for women above 40 years in low- and middle-income countries and that presents a feasible strategy for an emerging country. We believe that these results can be adapted to other emerging countries with similar BC incidence rates and public healthcare structures.

In conclusion, SFM every 2 years for all women starting between the ages of 40 and 49 would be a cost-effectiveness strategy to be incorporated by the Brazilian public healthcare system. Taking into account regional specificities, age-targeted digital screening is one option to improve the outcomes of BC patients in an emerging country.
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